Seizert Capital Partners LLC Makes New $4.45 Million Investment in Solventum Corporation (NYSE:SOLV)

Seizert Capital Partners LLC purchased a new stake in Solventum Corporation (NYSE:SOLV) in the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 58,550 shares of the company’s stock, valued at approximately $4,452,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Perigon Wealth Management LLC raised its holdings in Solventum by 3.8% in the 1st quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company’s stock valued at $331,000 after buying an additional 159 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of Solventum by 22.3% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 937 shares of the company’s stock valued at $71,000 after acquiring an additional 171 shares during the period. EP Wealth Advisors LLC lifted its holdings in shares of Solventum by 3.6% in the 4th quarter. EP Wealth Advisors LLC now owns 5,272 shares of the company’s stock worth $348,000 after acquiring an additional 181 shares during the last quarter. Brown Lisle Cummings Inc. boosted its position in shares of Solventum by 22.0% during the 1st quarter. Brown Lisle Cummings Inc. now owns 1,038 shares of the company’s stock worth $79,000 after purchasing an additional 187 shares during the period. Finally, Calamos Advisors LLC increased its holdings in Solventum by 1.1% in the 1st quarter. Calamos Advisors LLC now owns 18,620 shares of the company’s stock valued at $1,416,000 after purchasing an additional 207 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on SOLV shares. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target on the stock in a research note on Tuesday, July 1st. KeyCorp assumed coverage on Solventum in a report on Friday, June 6th. They set a “sector weight” rating for the company. Morgan Stanley raised Solventum from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Piper Sandler raised shares of Solventum from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $78.00 to $87.00 in a research note on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $84.38.

Solventum Price Performance

Shares of NYSE SOLV opened at $73.56 on Wednesday. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.19 and a quick ratio of 0.85. The company has a market cap of $12.73 billion, a price-to-earnings ratio of 34.05, a price-to-earnings-growth ratio of 1.89 and a beta of 0.55. The stock’s 50-day moving average is $74.17 and its two-hundred day moving average is $72.99. Solventum Corporation has a 1-year low of $54.26 and a 1-year high of $85.92.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, May 8th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.15. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. Solventum had a net margin of 4.55% and a return on equity of 31.01%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.08 earnings per share. Analysts forecast that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.